Sectors
The cash is being provided in the form of equity and an access fee as the two companies form a partnership agreement to improve drug delivery systems.
Allscripts purchased a 10% stake in the cloud-based healthcare IT company, following on from a strategic partnership formed by the two in March this year.
NantCell, an immuno-oncology subsidiary of conglomerate NantWorks, has acquired biotechnology company VivaBioCell, providing Generali with an exit.
Spinifex had raised just over $60m in funding, including $45m in a Novo-backed series C round in April 2014.
The biotechnology company previously raised more than $100m from investors including Medimmune, a subsidiary of pharmaceutical company AstraZeneca.
The virtual health services company has raised more than $70m in the past 18 months from backers including Sutter Health and Sentara Healthcare.
The tissue healing technology startup raised the first tranche of the round from backers including Heraeus' medical component subsidiary.
Clementia will use the cash to advance its fibrodysplasia ossificans progressiva treatment through Phase 2 clinical trials.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
